Pharmalot
Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.
Most Read
Pharmalittle: Lilly and Roche are also losers in the Medicare Alzheimer’s decision; former CRO owner pleads guilty to falsifying data
The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s competitors
Pharmalittle: Medicare proposes to restrict coverage of Biogen Alzheimer’s drug; Pfizer to cut its U.S. sales staff
‘Skinny label’ for generic version of a pricey cancer drug cut costs for consumers
Pharmalittle: Biogen CEO admits Alzheimer’s drug price was ‘wrong’; Becerra orders HHS to reconsider Medicare premium hike
Trial by fire: More study protocols are experiencing substantial — and costly — changes
A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs
All Coverage
advertisement
